KAS
JNCE

Kestra Advisory Services’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Kestra Advisory Services’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-26,100
Closed -$48.3K – 2217
2023
Q1 		$48.3K Hold
26,100
– – ﹤0.01% 1996
2022
Q4 		$29K Sell
26,100
-10,250
-28% -$14.6K ﹤0.01% 2208
2022
Q3 		$85K Buy
36,350
+10,100
+38% +$35.8K ﹤0.01% 1999
2022
Q2 		$80K Buy
26,250
+800
+3% +$3.89K ﹤0.01% 2006
2022
Q1 		$173K Hold
25,450
– – ﹤0.01% 1877
2021
Q4 		$213K Hold
25,450
– – ﹤0.01% 1841
2021
Q3 		$189K Hold
25,450
– – ﹤0.01% 1984
2021
Q2 		$173K Sell
25,450
-1
-0% -$8 ﹤0.01% 1894
2021
Q1 		$261K Sell
25,451
-10,249
-29% -$112K ﹤0.01% 1550
2020
Q4 		$238K Buy
35,700
+10,250
+40% +$79.8K ﹤0.01% 1609
2020
Q3 		$208K Buy
+25,450
New +$158K ﹤0.01% 1281

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Kestra Advisory Services's JNCE Position: Q2 2023 in Review

Kestra Advisory Services sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 26,100 shares — an estimated $48.3K sold.

Kestra Advisory Services first reported a position in JNCE in Q3 2020 and held it in 11 quarters. The position peaked at $261K in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Kestra Advisory Services reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Kestra Advisory Services sold 26,100 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $48.3K.
  • Kestra Advisory Services first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2020 and held it in 11 quarters.
  • Kestra Advisory Services's Jounce Therapeutics, Inc. Common Stock position peaked at $261K in Q1 2021.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Kestra Advisory Services's 13F filing for Q2 2023, filed 11 Aug 2023.